Circulating concentrations of 13,14-dihydro-15-keto PGF2 alpha (DHKF2 alpha), luteinizing hormone (LH) and prolactin (PRL) have been measured in cyclic ewes treated with continuous infusions of oxytocin, in order to investigate the mechanism by which the treatment delays luteal regression. Continuous infusion of oxytocin reduced prostaglandin F2 alpha (PGF2 alpha) secretion but had no detectable direct effect on LH or PRL. Oxytocin (3 nmol h-1 i.v.) given from Day 12 or 13 until Day 18 after oestrus delayed luteolysis, eight out of nine treated ewes not returning to behavioural oestrus until Day 29.1 +/- 3.2 (mean +/- s.e.m.; cycle length of control ewes 16.7 +/- 0.3 days). In the ewe in which oxytocin failed to prevent luteolysis, luteal regression had commenced before oxytocin treatment was started. In three ewes undergoing delayed luteolysis (cycle lengths, 21, 24 and 25 days) basal concentrations of PGF2 alpha (measured as DHKF2 alpha) were unchanged, but there was only one episode of PGF2 alpha secretion compared with 20 episodes in three control ewes. Prolactin secretion was pulsatile during oxytocin infusion, and levels were low following infusion in ewes with cycle length greater than 25 days while the corpora lutea were maintained. Circulating PRL concentrations were high in ewes undergoing delayed luteolysis but there was not discrete episode of PRL secretion associated with the pre-ovulatory LH surge in these animals. To investigate the possibility that the pattern of PGF2 alpha secretion was affected by depletion of oxytocin from corpora lutea, ewes previously treated with oxytocin to delay luteolysis were given a luteolytic dose of cloprostenol on Day 21 after oestrus. The amount of oxytocin secreted in response to cloprostenol was less than 10% of that seen in ewes similarly treated on Days 11-13 after oestrus. Low levels of luteal oxytocin may therefore reduce PGF2 alpha secretion in ewes undergoing delayed luteolysis.

Download full-text PDF

Source
http://dx.doi.org/10.1071/rd9900089DOI Listing

Publication Analysis

Top Keywords

pgf2 alpha
24
alpha secretion
20
delayed luteolysis
16
ewes treated
12
ewes undergoing
12
undergoing delayed
12
oxytocin
11
alpha
10
ewes
10
continuous infusion
8

Similar Publications

Biomarkers in the diagnosis of mast cell activation.

Curr Opin Allergy Clin Immunol

February 2025

Division of Allergic Diseases, Mayo Clinic Rochester, Rochester, Minnesota, USA.

Purpose Of Review: Mast cell activation is defined by activation of mast cells by varying stimuli with release of chemical mediators either through degranulation or release of de novo synthesized proteins or lipid mediators. Currently, tryptase measurement increase during symptomatic episodes is the most accepted biomarker measurement for mast cell activation. However, newer diagnostic tools including clinically available urinary mast cell mediators are noninvasive and can be more readily obtained compared to serum tryptase levels.

View Article and Find Full Text PDF

Evaluation of prevalence, risk factors, and therapeutic approach for subclinical endometritis and oviductal occlusion in repeat breeder Holstein cattle.

Res Vet Sci

February 2025

Unit of Reproduction and Obstetrics, Department of Animal Pathology. Faculty of Veterinary Medicine, Universidade de Santiago de Compostela (USC), 27002 Lugo, Spain; Instituto de Biodiversidade Agraria e Desenvolvemento Rural (IBADER), USC, Lugo University Campus s/n, 27002 Lugo, Spain. Electronic address:

Due to the productive and economic consequences of Repeat Breeder (RB) syndrome, the objectives of this study were to determine the prevalence and risk factors for subclinical endometritis (SE) and oviductal occlusion (OO) in RB cows, and to make a therapeutic approach for these pathologies. In 99 RB cows, endometrial cytologies were performed to assess the presence of SE (>5 % polymorphonuclear neutrophils), and the oviductal patency was checked using the phenolsulfonphthalein test. Body condition score was evaluated, and data from each animal were obtained from on-farm software (parity, calving date, artificial insemination (AI) date, number of AI, and occurrence of postpartum diseases).

View Article and Find Full Text PDF

The main objectives of the present study were to determine the effects of presynchronizing with a 1.0 g intravaginal progesterone device (IVPD) and prostaglandin F2α and to assess the effects of re-utilization of IVPD in a 2x2 factorial design, on the ovulatory response to first GnRH, ovarian status at different protocol stages, estrus expression and fertility in beef heifers submitted to a 5d-CO-Synch + Progesterone (P4) protocol. Beef heifers (n = 564) were assigned to 1 of 2 treatments at D-15: Pres5 (n = 283), where heifers received a (IVPD) for 5 days and administration of prostaglandin F2α (25 mg of dinoprost) at D-10; and Control (n = 281), where heifers received no treatment.

View Article and Find Full Text PDF

Long-term use of topical prostaglandins might initiate chronic conjunctival inflammation, leading to poor outcomes of glaucoma surgery. The aim of this study was to evaluate the immunoexpression pattern of HSP70, CTGF, SNAIL, aSMA, cMYB, and HIFa in the conjunctiva, episclera, and deep sclera in patients with glaucoma undergoing deep sclerectomy in order to establish an association between staining intensities and prostaglandin F2 (PGF2) treatment. Double immunofluorescence (HSP70, CTGF, SNAIL, aSMA, cMYB, and HIFa) was performed on conjunctiva, episclera, and deep sclera samples, which were obtained from 23 patients treated with PGF2 and 8 patients without PGF2 treatment.

View Article and Find Full Text PDF

The aims of this study were to: 1) evaluate the impact of intravaginal progesterone (P4) inserts containing different amounts of P4 on pregnancy rates of predominantly Bos taurus beef cows exposed to fixed-time artificial insemination (FTAI) using estradiol and P4-based synchronization protocols, and 2) evaluate the impact of delayed luteolysis on the fertility of cows receiving P4 insert with less P4. Cows (n = 1744) were randomly assigned to 1 of 3 treatments: 1) 2.0 mg of estradiol benzoate together with an intravaginal P4-releasing insert containing 1.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!